CliffBio
small molecule

OXANDROLONE

OXANDROLONE

Loss of exclusivity—loss of exclusivity
CompanyPar →See this company's full patent-cliff portfolio

Drug detail

Brand nameOXANDROLONE
Active ingredientOXANDROLONE
Strength2.5MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJune 2007
Marketing statusDISCN

More from Par

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

OXANDROLONE patent cliff — loss of exclusivity — | CliffBio